US20080176306A1 - Methods for Sterilizing Biological Materials - Google Patents

Methods for Sterilizing Biological Materials Download PDF

Info

Publication number
US20080176306A1
US20080176306A1 US11/843,165 US84316507A US2008176306A1 US 20080176306 A1 US20080176306 A1 US 20080176306A1 US 84316507 A US84316507 A US 84316507A US 2008176306 A1 US2008176306 A1 US 2008176306A1
Authority
US
United States
Prior art keywords
method
irradiation
kgy
bone
biological material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/843,165
Inventor
Martin J. MacPhee
Randall S. Kent
Edward A. Horton
Dawson Beall
Original Assignee
Macphee Martin J
Kent Randall S
Horton Edward A
Dawson Beall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/095,698 priority Critical patent/US5362442A/en
Priority to PCT/CA1994/000401 priority patent/WO1995003071A1/en
Priority to US08/573,149 priority patent/US6171549B1/en
Priority to US53354700A priority
Priority to US10/694,734 priority patent/US20040101437A1/en
Application filed by Macphee Martin J, Kent Randall S, Horton Edward A, Dawson Beall filed Critical Macphee Martin J
Priority to US11/843,165 priority patent/US20080176306A1/en
Publication of US20080176306A1 publication Critical patent/US20080176306A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029Radiation
    • A61L2/0035Gamma radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029Radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029Radiation
    • A61L2/0076Radiation using a photocatalyst or photosensitiser
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2202/00Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20Targets to be treated
    • A61L2202/22Blood or products thereof

Abstract

Methods are disclosed for sterilizing biological products to reduce the level of active biological contaminants such as viruses, bacteria, yeasts, molds, mycoplasmas and parasites.

Description

  • This application is a continuation application of U.S. application Ser. No. 10/694,734 (Oct. 29, 2003), which is a continuation application of U.S. application Ser. No. 09/533,547 (Mar. 23, 2000), which is a continuation-in-part application of U.S. application Ser. No. 08/573,149 (Dec. 15, 1995, now U.S. Pat. No. 6,171,549), which is a continuation-in-part application of PCT International Patent No. PCT/CA94/00401 (Jul. 22, 1994), which is a continuation-in-part application of U.S. application Ser. No. 08/095,698 (filed Jul. 22, 1993, now U.S. Pat. No. 5,362,442), all of which are herein incorporated by reference in their entireties.
  • FIELD OF THE INVENTION
  • The present invention relates to methods for sterilizing biological materials to reduce the level of active biological contaminants therein, such as viruses, bacteria, yeasts, molds, mycoplasmas and/or parasites.
  • BACKGROUND OF THE INVENTION
  • Several products that are prepared from human, veterinary or experimental use may contain unwanted and potentially dangerous contaminants such as viruses, bacteria, yeasts, molds, mycoplasmas and parasites. Consequently, it is of utmost importance that any biologically active contaminant in the product be inactivated before the product is used. This is especially critical when the product is to be administered directly to a patient, for example in blood transfusions, organ transplants and other forms of human therapies. This is also critical for various biotechnology products which are grown in media which contain various types of plasma and which may be subject to mycoplasma or other viral contaminants.
  • Previously, most procedures have involved methods that screen or test products for a particular contaminant rather than removal or inactivation of the contaminant from the product. Products that test positive for a contaminant are merely not used. Examples of screening procedures include the testing for a particular virus in human blood from blood donors. Such procedures, however, are not always reliable and are not able to detect the presence of viruses in very low numbers. This reduces the value or certainty of the test in view of the consequences associated with a false negative result. False negative results can be life threatening in certain cases, for example in the case of Acquired Immune Deficiency Syndrome (AIDS). Furthermore, in some instances it can take weeks, if not months, to determine whether or not the product is contaminated.
  • More recent efforts have focused in methods to remove or inactivate contaminants in the products. Such methods include heat treating, filtration and the addition of chemical inactivants or sensitizers to the product. Heat treatment requires that the product be heated to approximately 60° C. for about 70 hours which can be damaging to sensitive products. Heat inactivation can destroy up to 50% of the biological activity of the product. Filtration involves filtering the product in order to physically remove contaminants. Unfortunately this method may also remove products that have a high molecular weight. Further, in certain cases small viruses may not be removed by the filter because of the larger molecular structure of the product. The procedure of chemical sensitization involves the addition of noxious agents which bind to the DNA/RNA of the virus and which are activated either by UV or ionizing radiation to produce free radicals which break the chemical bonds in the backbone of the DNA/RNA of the virus or complex it in such a way that the virus can no longer replicate. This procedure requires that unbound sensitizer is washed from cellular products since the sensitizers are toxic, if not mutagenic or carcinogenic, and can not be administered to a patient.
  • Irradiating a product with gamma radiation is another method of sterilizing a product. Gamma radiation is effective in destroying viruses and bacteria when given in high total doses (Keathly et al., “Is There Life After Irradiation? Part 2,” BioPharm July-August, 1993, and Leitman, Use of Blood Cell Irradiation in the Prevention of Post Transfusion Graft-vs-Host Disease,” Transfusion Science 10:219-239 (1989)). The published literature in this area, however, teaches that gamma radiation can be damaging to radiation sensitive products, such as blood. In particular, it has been shown that high radiation doses are injurious to red cells, platelets and granulocytes (Leitman). U.S. Pat. No. 4,620,908 discloses that protein products must be frozen prior to irradiation in order to maintain the viability of the protein product. This patent concludes that “[i]f the gamma irradiation were applied while the protein material was at, for example, ambient temperature, the material would be also completely destroyed, that is the activity of the material would be rendered so low as to be virtually ineffective.” Unfortunately, many sensitive biologicals, such as blood, would lose viability and activity if subjected to freezing for irradiation purposes and then thawing prior to administration to a patient.
  • In view of the difficulties discussed above, there remains a need for methods of sterilizing biological materials that are effective for reducing the level of active biological contaminants without an adverse effect on the biological material.
  • SUMMARY OF THE INVENTION
  • Accordingly, it is an object of the present invention to provide methods of sterilizing biological materials by reducing the level of active biological contaminants without adversely effecting the biological material. Other objects, features and advantages of the present invention will be set forth in the detailed description of preferred embodiments that follows, and in part will be apparent from the description or may be learned by practice of the invention. These objects and advantages of the invention will be realized and attained by the compositions and methods particularly pointed out in the written description and claims hereof.
  • In accordance with these and other objects, a first embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) reducing the residual solvent content of a biological material to a level effective to protect the biological material from ionizing radiation; and (ii) irradiating the biological material with radiation at an effective rate for a time effective to sterilize the biological material.
  • A second embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) adding to a biological material at least one stabilizer in an amount effective to protect the biological material from ionizing radiation; and (ii) irradiating the biological material with radiation at an effective rate for a time effective to sterilize the biological material.
  • A third embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) reducing the residual solvent content of a biological material to a level effective to protect the biological material from ionizing radiation; (ii) adding to the biological material at least one stabilizer in an amount effective to protect the biological material from ionizing radiation; and (iii) irradiating the biological material with radiation at an effective rate for a time effective to sterilize the biological material.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS A. DEFINITIONS
  • Unless defined otherwise, all technical and scientific terms used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the relevant art. All patents and publications mentioned herein are expressly incorporated by reference.
  • As used herein, the term “biological material” is intended to mean any substance derived or obtained from a living organism. Illustrative examples of biological materials include, but are not limited to, the following: cells; tissues; blood or blood components; proteins, including recombinant and transgenic proteins; botanicals; foods and the like. Preferred examples of biological materials include, but are not limited to, the following: ligaments; tendons; nerves; bone, including demineralized bone matrix, grafts, joints, femurs, femoral heads, etc.; teeth; skin grafts; bone marrow, including bone marrow cell suspensions, whole or processed; heart valves; cartilage; corneas; arteries and veins; organs for transplant, such as hearts, lungs, liver, kidney, intestine, pancreas, limbs and digits; lipids; carbohydrates; collagen (native, afibrillar, atelomeric, soluble and insoluble); chitin and its derivatives including chitosan and its derivatives including NO-carboxy chitosan (NOCC); stem cells, islet of langerhans cells, and other cellular transplants, including genetically altered cells; red blood cells; white blood cells, including monocytes and stem cells; and platelets.
  • As used herein, the term “sterilize” is intended to mean a reduction in the level of at least one active biological contaminant found in the biological material being treated according to the present invention.
  • As used herein, the term “biological contaminant” is intended to mean a contaminant that, upon direct or indirect contact with a biological material, may have a deleterious effect on a biological material. Such biological contaminants include the various viruses, bacteria and parasites known to those of skill in the art to generally be found in or infect biological materials such as whole blood or blood components. Examples of biological contaminants include, but are not limited to, the following: viruses, such as human immunodeficiency viruses and other retroviruses, herpes viruses, paramyxoviruses, cytomegaloviruses, hepatitis viruses (including hepatitis B and hepatitis C), pox viruses, toga viruses, Ebstein-Barr virus and parvoviruses; bacteria, such as Escherichia, Bacillus, Campylobacter, Streptococcus and Staphalococcus; parasites, such as Trypanosoma and malarial parasites, including Plasmodium species; yeasts; molds; mycoplasmas; and prions. As used herein, the term “active biological contaminant” is intended to mean a biological contaminant that is capable of causing the deleterious effect.
  • As used herein, the term “blood components” is intended to mean one or more of the components that may be separated from whole blood and include, but are not limited to, cellular blood components, such as red blood cells, white blood cells and platelets; blood proteins, such as blood clotting factors, enzymes, albumin, plasminogen, fibrinogen and immunoglobulins; and liquid blood components, such as plasma and plasma-containing compositions.
  • As used herein, the term “cellular blood component” is intended to mean one or more of the components of whole blood that comprises cells, such as red blood cells, white blood cells or platelets.
  • As used herein, the term “blood protein” is intended to mean one or more of the proteins that are normally found in whole blood. Illustrative examples of blood proteins found in mammals (including humans) include, but are not limited to, coagulation proteins (both vitamin K-dependent, such as Factor VII or Factor IX, and non-vitamin K-dependent, such as Factor VIII and von Willebrands factor), albumin, lipoproteins (high density lipoproteins and/or low density lipoproteins), complement proteins, globulins (such as immunoglobulins IgA, IgM, IgG and IgE), and the like. A preferred group of blood proteins include Factor I (Fibrinogen), Factor II (Prothrombin), Factor III (Tissue Factor), Factor IV (Calcium), Factor V (Proaccelerin), Factor VI (Accelerin), Factor VII (Proconvertin, serum prothrombin conversion), Factor VIII (Antihemophiliac factor A), Factor IX (Antihemophiliac factor B), Factor X (Stuart-Prower Factor), Factor XI (Plasma thromboplastin antecedent), Factor XII (Hageman Factor), Factor XIII (Protansglutamidase), von Willebrand Factor (vWF), Factor Ia, Factor IIa, Factor Va, Factor VIa, Factor VIIa, Factor VIIIa, Factor IXa, Factor Xa, and Factor XIIIa.
  • As used herein, the term “liquid blood component” is intended to mean one or more of the fluid, non-cellular components of whole blood, such as plasma (the fluid, non-cellular portion of the blood of humans or animals as found prior to coagulation) or serum (the fluid, non-cellular portion of the blood of humans or animals after coagulation).
  • As used herein, the term “a biologically compatible solution” is intended to mean a solution to which biological materials may be exposed, such as by being suspended or dissolved therein, and remain viable, i.e., retain their essential biological and physiological characteristics. Such biologically compatible solutions preferably contain an effective amount of at least one anticoagulant.
  • As used herein, the term “a biologically compatible buffered solution” is intended to mean a biologically compatible solution having a pH and osmotic properties (e.g., tonicity, osmolality and/or oncotic pressure) suitable for maintaining the integrity of biological materials. Suitable biologically compatible buffered solutions typically have a pH between 5 and 8.5 and are isotonic or only moderately hypotonic or hypertonic. Biologically compatible buffered solutions are known and readily available to those of skill in the art.
  • As used herein, the term “stabilizer” is intended to mean a compound or material that reduces any damage to the biological material being irradiated to a level that is insufficient to preclude the safe and effective use of that material. Illustrative examples of stabilizers include, but are not limited to, the following: antioxidants, such as ascorbic acid and tocopherol; and free radical scavengers, such as ethanol, including Type I and Type II free radical scavengers, preferably at least one Type I and at least one Type II free radical scavenger. Preferred examples of stabilizers include, but are not limited to, the following: fatty acids, including 6,8-dimercapto-octanoic acid (lipoic acid) and its derivatives and analogues (alpha, beta, dihydro, bisno and tetranor lipoic acid), thioctic acid, 6,8-dimercapto-octanoic acid, dihydrolopoate(DL-6,8-dithioloctanoic acid methyl ester), lipoamide, bisonor methyl ester and tatranor-dihydrolipoic acid, furan fatty acids, oleic and linoleic and palmitic acids and their salts and derivatives; flavonoids, phenylpropaniods, and flavenols, such as quercetin, rutin and its derivatives, apigenin, aminoflavone, catechin, hesperidin and, naringin; carotenes, including beta-carotene; Co-Q10; xanthophylls; polyhydric alcohols, such as glycerol, mannitol; sugars, such as xylose, glucose, ribose, mannose, fructose and trehalose; amino acids, such as histidine, N-acetylcysteine (NAC), glutamic acid, tryptophan, sodium carpryl N-acetyl tryptophan and methionine; azides, such as sodium azide; enzymes, such as Superoxide Dismutase (SOD) and Catalase; uric acid and its derivatives, such as 1,3-dimethyluric acid and dimethylthiourea; allopurinol; thiols, such as glutathione and cysteine; trace elements, such as selenium; vitamins, such as vitamin A, vitamin C (including its derivatives and salts such as sodium ascorbate and palmitoyl ascorbic acid) and vitamin E (and its derivatives and salts such as tocopherol acetate and alpha-tocotrienol); chromanol-alpha-C6; 6-hydroxy-2,5,7,8-tetramethylchroma-2 carboxylic acid (Trolox) and derivatives; extraneous proteins, such as gelatin and albumin; tris-3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186); citiolone; puercetin; chrysin; dimethyl sulfoxide (DMSO); piperazine diethanesulfonic acid (PIPES); imidazole; methoxypsoralen (MOPS); 1,2-dithiane-4,5-diol; reducing substances, such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT); cholesterol; probucol; indole derivatives; thimerosal; lazaroid and tirilazad mesylate; proanthenols; proanthocyanidins; ammonium sulfate; Pegorgotein (PEG-SOD); N-tert-butyl-alpha-phenylnitrone (PBN); and 4-nydroxy-2,2,6,6-Tetramethylpiperidin-1-oxyl (Tempol).
  • As used herein, the term “residual solvent content” is intended to mean the amount of freely-available liquid in the biological material. Freely-available liquid means that liquid, such as water or an organic solvent (e.g. ethanol, isopropanol, polyethylene glycol, etc.), present in the biological material that is not bound to or complexed with one or more of the non-liquid components of the biological material (e.g. proteins, metal ions or salts, etc.). Freely-available liquid includes intracellular water. The residual solvent contents referenced herein refer to levels determined by the FDA approved, modified Karl Fischer method (Meyer and Boyd, Analytical Chem., 31, 215-219, 1959; May, et al., J. Biol. Standardization, 10, 249-259, 1982; Centers for Biologics Evaluation and Research, FDA, Docket No. 89D-0140, 83-93; 1990).
  • As used herein, the term “sensitizer” is intended to mean a substance that selectively targets viral, bacterial, and/or parasitic contaminants, rendering them more sensitive to inactivation by radiation, therefore permitting the use of a lower rate of radiation and/or a shorter time of irradiation than in the absence of the sensitizer. Illustrative examples of suitable sensitizers include, but are not limited to, the following: psoralen and its derivatives and analogs (including 3-carboethoxy psoralens); angelicins, khellins and coumarins which contain a halogen substituent and a water solubilization moiety, such as quaternary ammonium ion or phosphonium ion; nucleic acid binding compounds; brominated hematoporphyrin; phthalocyanines; purpurins; porphorins; halogenated or metal atom-substituted derivatives of dihematoporphyrin esters, hematoporphyrin derivatives, benzoporphyrin derivatives, hydrodibenzoporphyrin dimaleimade, hydrodibenzoporphyrin, dicyano disulfone, tetracarbethoxy hydrodibenzoporphyrin, and tetracarbethoxy hydrodibenzoporphyrin dipropionamide; doxorubicin and daunomycin, which may be modified with halogens or metal atoms; netropsin; BD peptide, S2 peptide; S-303 (ALE compound); dyes, such as hypericin, methylene blue, eosin, fluoresceins (and their derivatives), flavins, merocyanine 540; photoactive compounds, such as bergapten; and SE peptide.
  • As used herein, the term “proteinaceous material” is intended to mean a cellular material that comprises at least one protein or peptide. This material is preferably composed primarily of protein(s) and/or peptide(s). It may be a naturally occurring material, either in its native state or following processing/purification and/or derivatization. It may be artificially produced, either by chemical synthesis or utilizing recombinant/transgenic technology. Such artificially produced material may also be processed/purified and/or derivatized. Illustrative examples of proteinaceous materials include, but are not limited to, the following: proteins/peptides produced from tissue culture; milk (dairy products); ascites; hormones; growth factors; materials, including pharmaceuticals, extracted or isolated from animal tissue (such as heparin and insulin) or plant matter; plasma (including fresh, frozen and freeze-dried); fibrinogen, fibrinogen derivatives, fibrin, fibrin I, fibrin II, soluble fibrin and fibrin monomer, and/or fibrin sealant products; whole blood; protein C; protein S; alpha-1anti-trypsin (alpha-1 protease inhibitor); butyl-cholinesterase; anticoagulants, such as coumarin drugs (warfarin); streptokinase; tissue plasminogen activator (TPA); erythropoietin (EPO); urokinase; neupogen; anti-thrombin-3; alpha-glucosidase; (Fetal) Bovine Serum/Horse Serum; meat; immunoglobulins, including anti-sera, monoclonal antibodies, polyclonal antibodies and genetically engineered or produced antibodies; albumin; alpha-globulins; beta-globulins; gamma-globulins; coagulation proteins; complement proteins; and interferons.
  • As used herein, the term “ionizing radiation” is intended to mean radiation of sufficient energy to ionize (produce ions) the irradiated biological material. Types of ionizing radiation include, but are not limited to, the following: (i) corpuscular (streams of subatomic particles such as neutrons, electrons (including e-beam radiation), and/or protons); and (ii) electromagnetic (originating in a varying electromagnetic field, such as radio waves, visible and invisible light (including ultraviolet), x-radiation, and gamma rays).
  • B. PARTICULARLY PREFERRED EMBODIMENTS
  • A first preferred embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) reducing the residual solvent content of a biological material to a level effective to protect the biological material from ionizing radiation; and (ii) irradiating the biological material with radiation at an effective rate for a time effective to sterilize the biological material.
  • A second embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising:
  • (i) adding to a biological material at least one stabilizer in an amount effective to protect the biological material from ionizing radiation; and (ii) irradiating the biological material with radiation at an effective rate for a time effective to sterilize the biological material.
  • A third embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) reducing the residual solvent content of a biological material to a level effective to protect the biological material from ionizing radiation; (ii) adding to the biological material at least one stabilizer in an amount effective to protect the biological material from ionizing radiation; and (iii) irradiating the biological material with radiation at an effective rate for a time effective to sterilize the biological material. The order of steps (i) and (ii) may, of course, be reversed as desired.
  • The biological material sterilized in accordance with the methods of the present invention may be any material obtained or derived from a living or deceased organism, including a solid material or liquid material or a suspension of any solid(s) in any liquid(s) or a coating of any solid or liquid on a biological or non-biological substrate.
  • According to the methods of the present invention, the residual solvent content of the biological material is reduced prior to irradiation of the biological material with ionizing radiation. The residual solvent content is reduced to a level that is effective to protect the biological material from the ionizing radiation. Suitable levels of residual solvent content may vary depending upon the nature and characteristics of the particular biological material being irradiated and can be determined empirically by one skilled in the art. Preferably, when the solvent is water, the residual solvent content is less than about 2.0%, more preferably less than about 1.0%, even more preferably less than about 0.5% and most preferably less than about 0.2%.
  • While not wishing to be bound by any theory of operability, it is believed that the reduction in residual solvent content reduce the degrees of freedom of the biological material and thereby protects it from the effects of the ionizing radiation. Similar results might therefore be achieved by lowering the temperature of the biological material below its eutectic point or below its freezing point to likewise reduce the degrees of freedom of the biological material. These results permit the use of a higher rate of irradation than might otherwise be acceptable.
  • The residual solvent content of the biological material may be reduced by any of the methods and techniques known to those skilled in the art for removing solvent from a biological material. A particularly preferred method for reducing the residual solvent content of a biological material is lyophilization. According to a particularly preferred embodiment of the present invention, a biological material which has been lyophilized is stored under vacuum or an inert atmosphere (preferably a noble gas, such as helium or argon, more preferably a higher molecular weight noble gas, and most preferably argon) prior to irradation.
  • The ionizing radiation employed in the present invention may be any ionizing radiation effective for the inactivation of one or more biological contaminants of the biological material being treated. Preferably the ionizing radiation is electromagnetic radiation and a particularly preferred form of ionizing radiation is gamma radiation.
  • According to the methods of the present invention, the biological material is irradiated with the ionizing radiation at a rate effective for the inactivation of one or more biological contaminants of the biological material. Suitable rates of irradiation may vary depending upon the particular form of ionizing radiation and the nature and characteristics of the particular biological material being irradiated and the particular biological contaminants being inactivated. Suitable rates of irradiation can be determined empirically by one skilled in the art. Preferably, the rate of irradiation is constant for the duration of the sterilization procedure.
  • According to a particularly preferred embodiment of the present invention, the rate of irradiation is not more than about 3.0 kGy/hour, more preferably between about 0.1 kGy/hr. and 3.0 kGy/hr, even more preferably between about 0.25 kGy/hr and 2.0 kGy/hour, still even more preferably between about 0.5 kGy/hr and 1.5 kGy/hr and most preferably between about 0.5 kGy/hr and 1.0 kGy/hr.
  • According to another particularly preferred embodiment of the present invention, the rate of irradiation is at least about 3.0 kGy/hr., more preferably at least about 6 kGy/hr., even more preferably at least about 16 kGy/hr., and most preferably at least about 30 kGy/hr.
  • The biological material is irradiated with the ionizing radiation for a time effective for the inactivation of one or more biological contaminants of the biological material. Suitable irradiation times may vary depending upon the particular form and rate of ionizing radiation and the nature and characteristics of the particular biological material being irradiated and the particular biological contaminants being inactivated. Suitable irradiation times can be determined empirically by one skilled in the art.
  • Optionally, an effective amount of at least one sensitizer is added to the biological material prior to irradiation with ionizing radiation. Suitable sensitizers are known to those skilled in the art.
  • According to methods of the present invention, the irradiation of the biological material may occur at any temperature which is not deleterious to the biological material being treated. According to a preferred embodiment, the biological material is irradiated at ambient temperature. According to an alternate preferred embodiment, the biological material is irradiated at reduced temperature, preferably at or below the eutectic point of the biological material.
  • C. EXAMPLES
  • The following examples are illustrative, but not limiting, of the present invention. Other suitable modifications and adaptations are of the variety normally encountered by those skilled in the art and are fully within the spirit and scope of the present invention.
  • Example 1 Sterilization of Blood
  • A 200 ml bag of one day old packed red blood cells was used. Ethanol was added to the cells in order to achieve a final ethanol concentration of 0.01% v/v. The red blood cells were diluted by a factor of one in ten using a modified Citrate Phosphate Dextrose (CPD) solution having a pH of about 6.4 to 6.7 and having the following composition in a total volume of 500 ml:
  • Citrate Acid Monohydrate 0.2 g
    Sodium Citrate Dihydrate 27.3 g 
    Sodium Monobasic Phosphate 2.2 g
    Sodium Dibasic Phosphate 1.0 g
    Dextrose 3.2 g
  • The cells were irradiated in a commercial size gamma irradiator which contained a cobalt 60 source rack. Irradiation was done off carrier in an unprotected box. The cells were irradiated for twenty-four hours at a rate of approximately 1 kGy/hr. After the irradiation period the red blood cells were examined visually and were found to be viable, having a brilliant red color. A control sample, consisting of packed red blood cells that were not diluted with the above-described CPD solution, was not viable after irradiation.
  • Four days after the irradiation procedure, the diluted cells were tested for levels of various blood components and the results are shown in Table 1. The control sample consisted of blood from the same bag as the test sample but it did not undergo irradiation. Table 1 illustrates that dilution and irradiation of human blood cells did not significantly alter the white blood cell count. The platelet count and hematocrit values were slightly lower than the control; however, these values are still within the range that is seen in normal adult blood. The level of hemoglobin was higher than in the control indicating that some red blood cells did lyse during the procedure. This is also evidenced by the lower red blood cell count. Nevertheless, contrary to what has been previously published, up to 50 kGy of radiation did not destroy the components of blood by the present procedure. The cells were also counted and found to be viable after 25 kGy of gamma irradiation delivered at a low dose rate of 1 kGy/hr.
  • TABLE 1
    Component Irradiated Blood Control Blood
    White Blood Cells 4 K/mm3 4.8 K/mm3
    Red Blood Cells 3 Mi/mm3 7.2 Mi/mm3
    Hemoglobin 42 g/dl 21 g/dl
    Hematocrit 46% 64%
    Platelet 100 k/mm3 120 k/mm3
  • Example 2 Sterilization of Dextrose
  • Dextrose (or glucose) containing solutions are used in the treatment of carbohydrate and fluid depletion, in the treatment of hypoglycemia, as a plasma expander, in renal dialysis and to counteract hepatotoxins (The Merck Index, Eleventh Edition, Merck & Co., Inc. (1989), and Martindale's Extra Pharmacopecia, p. 1, 265). Dextrose is also the preferred source of carbohydrate in parental nutrition regiments (The Merck Index, Eleventh Edition, Merck & Co., Inc. (1989), and Martindale's Extra Pharmacopecia, p. 1, 265). In all of the above applications, the dextrose must be sterilized before use. Sterilization of dextrose-containing products is generally done by heat sterilization or autoclaving. Unfortunately, these methods have been reported to degrade or carmelize dextrose-containing solutions resulting in a color change in the solution (Martindale's Extra Pharmacopecia, p. 1, 265). Gamma irradiation of glucose has also been reported to decompose glucose-containing solutions (Kawakishi, et al., “Radiation-Induced Degradation of D-glucose in Anaerobic Contition,” Agric. Biol. Chem., June 1977). Therefore, there is a need for a method that can sterilize dextrose-containing products that does not degrade the product itself. In view of the problems of the prior art, a dextrose solution was treated according to the method of the present invention as follows.
  • A 5% dextrose solution was irradiated for 24 hours, at a rate of approximately 1 kGy/hr. After irradiation, the product was tested and it was found that there was no visible light spectrum change as compared to the non-irradiated control. Therefore, the present method can be useful in sterilizing products that contain dextrose.
  • In addition to the above experiment, fresh solutions of 5% and 50% dextrose were irradiated to 25 kGy over 36 hours at ambient temperature. The results were similar to those described above. In addition, UV/VIS scans were obtained and demonstrated a complete absence of the peak at 283.4 nm for “furfural” as per U.S.P. In contrast, dextrose samples sterilized using an autoclave contain the 283.4 furfural peak. “Furfurals” are carcinogenic.
  • Example 3 Sterilization of Human Serum Albumin
  • Normal Human Serum Albumin was irradiated as a 25% salt-poor solution to a total dose of 25 kGy over 36 hours using a Gammacell 220 (Co60 is the gamma ray source in this instrument). The temperature was not controlled during the irradiation but it is estimated that the container holding the albumin solution was approximately 23° C. The results of HPLC analysis are given in Table 2.
  • TABLE 2
    Parameter Control (%) Irradiated (%)
    Polymer 2 3
    Dimer 7 8
    Monomer 90 86
    Low Molecular Weight 1 3
    pH 7.05 6.97
    NTU (must be >20) 11.4 11.4
  • As the results demonstrate, Normal Human Serum Albumin can safely be irradiated to 25 kGy (at a rate of approximately 0.7 kGy/hr) at room temperature without adversely affecting the essential properties of the protein. This has not been demonstrated before. All other attempts at irradiating serum albumin require that it be irradiated in the frozen stage. This adds to the cost and difficulty of doing the irradiation.
  • Example 4
  • Normal human blood from a healthy donor was taken in a heparinized tube, washed three times with standard CPD solution, then diluted 1:20 with CPD containing 0.01% v/v Ethanol. This latter solution of CPD with 0.01% v/v Ethanol is called SCPD. Two ml aliquots were then placed in 10 ml plastic test tubes and irradiated to different doses up to 26 kGy over 36 hours at room temperature. There was no haemolysis and the cells appeared intact if somewhat large and slightly irregular in shape. The results of three separate experiments are reported in Table 3.
  • TABLE 3
    Parameter RCB1 HGB2 HCT3 MCV4 MCH5 MCHC6 RDW7 Flags
    1* 1.08 41 .097 89.5 38.3 427 17.7 Nearly
    Control .99 33 0.89 90.2 33.0 366 15.3 Normal
    2* 95.0 32.3 339 12.0
    12 kGy 1 1.22 45 .166 135.8 36.5 269 27.3 1 + Anisocytosis
    1.38 45 .199 144.7 33.0 228 24.9 3 + Macrocytocis
    1 1.04 32 .169 163.0 31.3 152 18.8 1 + Anisocytosis
    16 kGy 0.54 29 .088 162.5 54.5 335 18.8 3 + Macrocytocis
    2 0.82 27 .128 156.5 32.8 209 19.8 2 + Anisocytosis
    0.81 26 .124 152.6 32.4 212 20.2 3 + Macrocytocis
    1 0.79 244 .125 158.4 30.8 194 19.4 1 + Anisocytosis
    20 kGy 1.26 28 .203 161.5 22.1 137 19.0 3 + Macrocytocis
    2 0.93 30 .141 151.5 32.3 213 20.1 2 + Anisocytosis
    0.92 30 .143 155.5 32.1 207 20.5 3 + Macrocytocis
    26 kGy 1 1.15 34 .180 155.9 29.4 189 19.1 1 + Anisocytosis
    1.15 34 .176 153.0 29.9 195 23.4 3 + Macrocytocis
    *Experiment 1 and Experiment 2
    1Red Blood Cell Count: Cells × 1012/liter
    2Hemoglobin: grams/liter
    3Hematocrit
    4Mean Corpuscular Volume: Femtoliters
    5Mean Corpuscular Hemoglobin: picograms
    6Mean Corpuscular Hemoglobin Concentration: grams/liter
  • The cells were easily put into suspension and reconstituted in fresh buffer.
  • The following three experiments (Examples 5, 6 and 7) were conducted in order to determine the efficacy of the method when treating HIV-contaminated blood. In each Example the cells were similarly treated. In these experiments, the cells were gently agitated after 12, 16 and 24 hours of irradiation. Further, in the third experiment (Example 7), the cells were placed in T25 flasks to provide greater surface area and reduce the concentration due to settling in the bottom of the centrifuge tubes. In each case, the cells were irradiated at a dose rate of approximately 0.7 kGy/hr.
  • Example 5 Sterilization of HIV-Containing Blood
  • The following experiments were undertaken with the following specific objectives:
      • 1. To evaluate the toxicity of the process towards red blood cells (RBCs).
      • 2. To evaluate the anti-retroviral activity of the process.
    Procedure
  • Initially, 2 ml of anticoagulated blood was obtained from an HIV-seronegative donor. The blood was centrifuged, and the plasma was removed. The remaining cell pellet was resuspended in 10 ml of the CPD buffer and centrifuged. This washing process was repeated a total of three times. The final pellet was resuspended in 40 ml of the SCPD buffer, and distributed into plastic tubes in 2 ml aliquots, with 16 separate aliquots being retained for further manipulation. For 8 of these tubes, an aliquote of HTLV-IIIB was added. This is a laboratory strain of the HIV virus and 100 tissue culture infective doses (TCID) were added to each of the tubes to be infected. For the remaining 8 tubes, a “mock” infection was performed, by adding a small amount of non-infectious laboratory buffer, phosphate buffered saline (PBS). Four infected and four non-infected tubes were subjected to the process. For comparison, the remaining 8 tubes (four infected and four non-infected) were handled in an identical manner, except that they were not subjected to the process.
  • It should be stated that at the beginning of the study, a separate aliquot of blood was obtained from the donor. This was processed in the clinical hematology laboratory and a complete hemogram was performed. These baseline results were compared to repeat testing on the study aliquots, which included evaluation of four processed and four unprocessed samples, all of which were not infected with HIV.
  • An aliquot of 0.5 ml of each of the infected study samples was inoculated on mononuclear cells (MCs) which had been obtained three days earlier. These cells had been suspended in RMPI culture medium, with 10% fetal calf serum and other additives (penicillin, streptomycin, glutamine and HEPES buffer) along with 1 μg/ml PHA-P. At the same time as this inocculation, the cells were resuspended in fresh medium with rIL-2 (20 U/ml). The cultures were maintained for 7 days. Twice weekly, a portion of the culture medium was harvested for the measurement of HIV p24 antigen levels (commercial ELISA kit, Coulter Electronics, Hialeah, Fla.) for the measurement of viral growth.
  • A separate aliquot of the eight infected study samples was used for viral titration experiments. Briefly, serial four-fold dilutions of the virus-containing fluids (ranging from 1:16 to 1:65,536) were inoculated in triplicate in 96-well flat-bottom tissue culture plates. PHA-stimulated MCs were added to each well (4 million cells in 2 ml culture medium, with IL-2). An aliquot of the supernatant from each culture well was harvested twice weekly for the measurement of HIV p24 antigen levels. A well was scored as “positive” if the HIV p24 antigen value was >30 pg/ml.
  • The viral titer was calculated according to the Spearman-Karber method (se ACTG virology protocol manual) using the following equation:

  • M=xk+d[0.5−(1/n)r]
      • M: titer (in log 4)
      • xk: dose of highest dilution
      • d: space between dilutions
      • n: number of wells per dilution
      • r: sum of total number of wells.
    Results
  • Red blood cell parameters for the baseline sample as well as for the unprocessed and processed study samples are shown in Table 4.
  • TABLE 4
    Sample/Number MCV MCH MCHC
    Baseline 94.5 32.0 339
    Unprocessed-1 91.4 34.4 376
    Unprocessed-2 90.2 37.9 420
    Unprocessed-3 92.1 40.0 433
    Unprocessed-4 91.0 40.2 442
    Processed-1 133.4 37.8 284
    Processed-2 131.5 45.0 342
    Processed-3 128.5 38.9 303
    Processed-4 131.1 39.4 301
  • The abbreviations in Table 4 are explained under Table 3.
  • As described above, HIV cultures were established using 0.5 ml aliquots of unprocessed and processed study samples. P24 antigen levels (pg/ml) from the study samples on day 4 and day 7 of culture are shown in Table 5.
  • TABLE 5
    p24 p24
    Sample/Number Day 4 Day 7
    Unprocessed-1 1360 484
    Unprocessed-2 1180 418
    Unprocessed-3 1230 516
    Unprocessed-4 1080 563
    Processed-1 579 241
    Processed-2 760 303
    Processed-3 590 276
    Processed-4 622 203
  • Finally, one unprocessed sample and one processed sample were selected for the performance of direct viral titration without culture. The results are shown in Table 6.
  • TABLE 6
    Sample/Number Titer (log 10 ml)
    Unprocessed-1 1.5
    Processed-1 0.0
  • The red blood cells were minimally affected by the process, although some reproducible macrocytosis was observed. Although on co-culturing of processed samples, there appeared to be some residual live virus, this was not confirmed by direct titration experiments.
  • Example 6
  • The objective of this experiment was to evaluate the toxicity of the process towards red blood cells in a comprehensive manner.
  • Methods
  • For this experiment, 1 ml of anticoagulated blood was obtained from the same HIV-seronegative donor as in the first experiment. The blood was centrifuged and the plasma was removed. The remaining cell pellet was resuspended in 10 ml of the CPD buffer and centrifuged. This washing process was repeated a total of three times. The final pellet was resuspended in 20 ml of the SCPD buffer and distributed into plastic tubes in 2 ml aliquots with all 10 aliquots being retained for further manipulation. Eight tubes were subjected to the process, while the final two tubes were retained as control, unprocessed tubes. After the processing, all the tubes were centrifuged, and the resulting pellet was resuspended in 100 μl buffer. A complete hemogram was performed on these reconcentrated study samples.
  • As in the first experiment, a separate aliquot of blood was obtained from the donor when the study sample was taken. A complete hemogram was performed on this baseline sample. As the study samples were re-concentrated to 33-50% of their original state, more direct comparisons with the baseline sample could be undertaken than were possible in our earlier experiment.
  • Results
  • Red blood cell parameters for the baseline sample as well as for the unprocessed and processed study samples are shown in Table 7. The abbreviations used in Table 7 are defined in Table 3.
  • TABLE 7
    Sample/
    Number RBC HGS MCV MCH MCHC
    Baseline 4.76 152 94.9 31.9 336
    Unprocessed-1 0.99 33 90.2 33.0 366
    Unprocessed-2 1.08 41 89.5 38.3 427
    Processed-1 1.15 34 153.0 29.9 195
    Processed-2 1.15 34 155.9 29.4 189
    Processed-3 1.26 28 161.5 22.1 137
    Processed-4 0.79 24 158.4 30.8 194
    Processed-5 0.54 29 162.5 54.5 335
    Processed-6 1.04 32 163.0 31.3 192
    Processed-7 1.35 45 144.7 33.0 228
    Processed-8 1.22 45 135.8 36.5 269
  • There was macrocytosis of the cells which was present in all the processed samples. Comparable hemoglobin levels were measured in the unprocessed and processed samples. The absolute values were appropriate for the residual dilution. The red blood cells are preserved.
  • Example 7 Methods
  • For this experiment, 5 ml of anticoagulated blood was obtained from the same HIV-seronegative donor as in the first two experiments. The blood was centrifuged, and the plasma was removed. The remaining cell pellet was resuspended in 100 ml of the CPD buffer, and centrifuged. This washing process was repeated a total of three times. The final pellet was resuspended in 100 ml of the SCPD buffer and distributed in 25 ml aliquots, in T25 tissue culture flasks, with all four aliquots being retained for further manipulation. Two flakes were subject to the process, while the other two were retained as control, unprocessed flasks. After the processing, the contents of each of the flasks was observed and a visual determination of the cells' capacity to absorb oxygen (turning a brighter red on exposure to ambient air) was made. Following this, the contents of the flasks were aspirated and centrifuged, with the residual pallet resuspended in a small volume of buffer. A complete hemogram was performed on these re-concentrated study samples.
  • As in Examples 5 and 6, a separate aliquot of blood was obtained from the donor when the study sample was taken. A complete hemogram was performed on this baseline sample. As the study samples were re-concentrated to 33-50% of their original state, direct comparisons of a number of specific parameters would be possible with the baseline sample.
  • Results
  • On visual inspection, there were no appreciable differences between the processed and unprocessed study samples. Specifically, there appeared to be a uniform distribution of well suspended cells. On exposure to ambient air, the contents of all flasks became somewhat brighter red. No specific quantitative measurements of oxygenation were made.
  • Red blood cell parameters for the baseline sample as well as for the unprocessed and processed study samples are shown in Table 8. The abbreviations used in Table 8 are defined under Table 3.
  • TABLE 8
    Sample/
    Number RBC HGS MCV MCH MCHC
    Baseline 4.75 153 95.0 32.3 339
    Unprocessed-1 0.93 30 151.5 32.3 213
    Unprocessed-2 0.92 30 155.5 32.1 207
    Processed-1 0.82 27 156.5 32.8 209
    Processed-2 0.81 26 152.6 32.4 212
  • This experiment was designed to more closely approximate conditions of red blood cells to be transfused into a patient, and was consequently conducted at higher volumes. On a preliminary basis, it does not appear that the process impairs the red blood cells' ability to carry oxygen, although this should be measured more formally. Interestingly, in this experiment, there was no difference in cell size between the processed and unprocessed samples, both being large compared to baseline. Comparable hemoglobin levels were measured in all the study samples.
  • Example 8
  • In this experiment, Immunoglobulin G (IgG) was irradiated in lyophilized form.
  • Method
  • The results of HPLC analysis of IgG are given in Table 9. As the results demonstrate, the product appears to be unaffected after being irradiated to a dose of 25 kGy at room temperature when the irradiation is delivered at a rate of approximately 0.7 kGy/hr. This has not been previously demonstrated.
  • TABLE 9
    Parameter Control (%) Irradiated (%)
    Polymer (must be >2%) 1 1
    Dimer 10 13
    Monomer 88 84
    Low Molecular Weight 1 2
  • The results presented by Gergely, et al., using freeze dried IgG showed that a portion of the protein was insoluble after an irradiation dose of 12 kGy to 25 kGy at standard irradiation dose rates. (Gergely, J., et al., “Studies of Gama-Ray-Irradiated Human Immunoglobulin G.” SM-92/12 I.A.E.A.) In contrast, using the present method at a dose rate of approximately 0.7 kGy/hr, none of the protein was insoluble. This would indicate that little or no change or degradation of the protein occurred. Further, Gergely, et al., found that a liquid formulation of human IgG lost all of its activity after irradiation. In studies using the present method on intravenous immunoglobulin (IVIG) in liquid form, it was shown that greater than 70% of a specific antibody in hyperimmune IVIG was retained.
  • Example 9
  • In this experiment, alpha 1 proteinase inhibitor and fibrinogen were irradiated in lyophilized form.
  • Method
  • The samples were placed in a Gammacell 220 and irradiated according to the present process to a total dose of 25 kGy. Samples were then returned to the laboratory for analysis. The dose rate was 0.72 kGy/hr.
  • Results
  • The alpha 1 proteinase inhibitor, both treated and control, were 40% of a standard normal pooled plasma sample. The Mancini radial immunodiffusion technique was used as the assay.
  • The topical fibrinogen complex vials were reconstituted in 10 ml of water. Protamine sulphate vials were reconstituted in 10 ml of water. Protamine sulphate at a concentration of 10 mg/ml was added to the samples. There was instant formation of monomer in all three preparations.
  • Example 10
  • In this experiment, Factors VII, VIII and IV were irradiated in lyophilized form.
  • Method
  • The samples were placed in a Gamacell 220 and irradiated to various total doses at a dose rate of approximately 1 kGy/hr.
  • Results
  • Factor VII retained 67% activity at 20 kGy and 75% at 10 kGy. Factor VIII retained 77% activity at 20 kGy and 88% at 10 kGy. Similarly, Factor IV showed an activity level of 70% at 20 kGy and 80% at 10 kGy.
  • Analysis
  • Excellent results were found for the three Factors. To our knowledge, no one has been able to achieve these results by irradiating the Factors at ambient temperature to such a high dose of radiation with such little loss of activity. This is in direct contrast with the results of Kitchen, et al, “Effect of Gamma Irradiation on the Human Immunodeficiency Virus and Human Coagulation Proteins,” Vox Sang 56:223-229 (1989), who found that “the irradiation of lyophilized concentrates is not a viable procedure.” Similarly, Hiemstra, et al., “Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors,” Transfusion 31:32-39 (1991), also concluded that “Gamma radiation must be disregarded as a method for the sterilization of plasma and plasma-derived products, because of the low reduction of virus infectivity at radiation doses that still give acceptable recovery of biologic activity of plasma components.”
  • Example 11
  • In this experiment, red blood cells were irradiated at a dose rate of 0.5 kGy/hr for periods of time ranging from 7.5 to 90 minutes in order to remove bacterial contaminants.
  • Method
  • Red blood cells were collected from a healthy donor in EDTA, washed 3 times with CPD solution and resuspended in DPC to provide a 1:20 dilution based on the original blood volume. The cell suspension was then subdivided into 14 tubes. To seven of the tubes, approximately 1.0×104 Staphylococcus epidermidia were added. The cells were placed on ice for transport to the irradiation facility. All of the samples were placed in the chamber at ambient temperature and irradiated at 0.5 kGy/hr for periods of time to give total doses of 0.625, 0.125, 0.250, 0.375, 0.500 and 0.750 kGy, respectively. The samples were removed and agitated at each time point and placed on ice for transport either to the microbiology lab or the hematology lab for analysis.
  • Results
  • The results of the microbiology assays are given in Table 10.
  • TABLE 10
    Radiation Dose (kGy) Time (Min.) Number Surviving
    0 92,200
    0.625 7.5 84,500
    0.125 15 35,000
    0.250 30 10,067
    0.375 45 1,800
    0.500 60 250
    0.750 90 0
  • Thus, a dose of 0.75 kGy provides a 4.5 log10 reduction in bacterial survivors. This represents a significant safety factor for blood. Further, the D10 value is approximately 0.125 kGy which corresponds well with the values reported in the literature for similar species of staphylococcus (B. A. Bridges, “The effect of N-Ethylmaleimide on the radiation sensitivity of bacteria,” J Gen. Microbiol. 26:467-472 (1962), and Jacobs, G. P. and Sadeh, N., “Radiosensitization of Staphyloccocus aureus by p-hydroxybenzoic acid,” Int. J. Radiat. Biol. 41:351-356 (1982).
  • In order to demonstrate that the red blood cells remained viable after the irradiation process, the following parameters were determined for the cells, WBC, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils. These determinations merely enumerated the number of cells present. All nucleated cells would, of course, be inactivated by the radiation dose delivered. The other red blood cell parameters monitored are listed in Table 11. The Methaemoglobin value was unchanged from that of the controls even after a radiation dose of 0.75 kGy. This experiment demonstrates that red blood cells can be safely irradiated by the present method to a dose of 0.75 kGy at room temperature with no loss of cell function.
  • Example 12
  • This experiment was conducted using the method in Example 11 to confirm the findings of Example 11 and to expand upon some of the parameters measured. The results of this experiment are given in Table 12.
  • Results
  • (See Table 12, below.)
  • These results confirm the previous results and indicate that indeed, red blood cells can be irradiated to a dose sufficient to provide 4.5 log10 reduction in bacterial count.
  • It is contemplated that future experiments will provide similar results for platelet. Thus, with little or no additional manipulation, and without the addition of extraneous materials, red blood cells can be treated by the present process to provide a bacteriologically safe product, thus further reducing the risk of untoward reactions in recipients.
  • TABLE 11
    Red Blood Cell Valus as a Function of Radiation Dose Received
    Total Dose (in kGy)
    Parameter Whole Blood 0 0.625 0.125 0.250 0.500
    RBC 5.06 1.49 1.27 1.77 1.73 1.43
    HGB 153 43 41 56 56 46
    HTC .483 .142 .120 .156 .163 1.31
    MCV 95.5 95.6 94.3 94.2 93.7 32.1
    MCH 31.2 31.1 32.2 31.7 32.2 32.5
    MCHC 327 325 341 336 344 353
    RDW 13.93 12.1 12.7 12.9 12.9 13.2
    METHgB 0.9 0.3 0.3 0.3 0.0 0.9
  • TABLE 12
    Red Blood Cell Values as a Function of Radiation Dose Received
    Total Dose (in kGy)
    Parameter 0 0.625 0.125 0.250 0.375 0.555 0.750
    HGB 1.8 1.7 1.8 1.7 2.0 2.0 2.0
    % O 96.6 96.5 96.2 96.3 96.4 96.5 96.0
    % CO 1.0 1.2 1.6 1.3 1.7 1.5 1.5
    % NET 0.5 0.5 −0.5 0.4 −0.2 0.4 0.8
    % Reduced 1.9 1.9 2.7 2.4 3.2 1.7 1.7
    p60 (mm Hg) 34 nd nd nd nd nd 24
    Hill 2.1 nd nd nd nd nd 1.8
    Coefficient
    nd = not done
    The uncertainty with the methaemoglobin levels is ±2%; with the p50 it is ±4% (95% confidence).
  • Having now fully described this invention, it will be understood to those of ordinary skill in the art that the methods of the present invention can be carried out with a wide and equivalent range of conditions, formulations, and other parameters without departing from the scope of the invention or any embodiments thereof. All patents and publications cited herein are hereby fully incorporated by reference in their entirety.

Claims (17)

1-26. (canceled)
27. A method for reducing the level of active biological contaminants or pathogens in bone, comprising
contacting the bone with a composition comprising DMSO, trehalose and mannitol; and
irradiating the bone-containing composition with gamma radiation,
wherein the total dose of gamma radiation is at least about 12 kGy.
28. The method of claim 27, wherein the bone-containing composition is below ambient temperature during irradiation.
29. The method of claim 27, wherein the bone-containing composition is at a temperature below its freezing point during irradiation.
30. The method of claim 27, wherein the irradiation is applied at a rate of at least about 0.1 kGy/hour to at least about 30.0 kGy/hour.
31. The method of claim 27, wherein the total dose of gamma irradiation is at least about 20 kGy.
32. The method of claim 27, wherein the total dose of gamma irradiation is at least about 26 kGy.
33. The method of claim 27, wherein the bone is demineralized bone matrix.
34. The method of claim 27, further comprising adjusting or maintaining the pH of the bone prior to irradiation.
35. The method of claim 27, further comprising reducing residual solvent content of the bone prior to irradiation.
36. The method of claim 35, wherein the residual solvent is a non-aqueous solvent.
37. The method of claim 35, wherein the residual solvent is an aqueous solvent.
38. The method of claim 35, wherein the residual solvent content is reduced to less than about 2.0%.
39. The method of claim 27, further comprising contacting the bone with at least one sensitizer prior to irradiation.
40. The method of claim 27, wherein the active biological contaminants or pathogens are selected from the group consisting of viruses, bacteria, yeasts, molds, parasites, prions and combinations thereof.
41. The method of claim 27 wherein the bone is maintained in an inert atmosphere during irradiation.
42. The method of claim 27 wherein the bone is maintained under vacuum during irradiation.
US11/843,165 1993-07-22 2007-08-22 Methods for Sterilizing Biological Materials Abandoned US20080176306A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US08/095,698 US5362442A (en) 1993-07-22 1993-07-22 Method for sterilizing products with gamma radiation
PCT/CA1994/000401 WO1995003071A1 (en) 1993-07-22 1994-07-22 Method for sterilizing products
US08/573,149 US6171549B1 (en) 1993-07-22 1995-12-15 Method for sterilizing products
US53354700A true 2000-03-23 2000-03-23
US10/694,734 US20040101437A1 (en) 1993-07-22 2003-10-29 Methods for sterilizing biological materials
US11/843,165 US20080176306A1 (en) 1993-07-22 2007-08-22 Methods for Sterilizing Biological Materials

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/843,165 US20080176306A1 (en) 1993-07-22 2007-08-22 Methods for Sterilizing Biological Materials

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/694,734 Continuation US20040101437A1 (en) 1993-07-22 2003-10-29 Methods for sterilizing biological materials

Publications (1)

Publication Number Publication Date
US20080176306A1 true US20080176306A1 (en) 2008-07-24

Family

ID=22253204

Family Applications (6)

Application Number Title Priority Date Filing Date
US08/095,698 Expired - Lifetime US5362442A (en) 1993-07-22 1993-07-22 Method for sterilizing products with gamma radiation
US08/573,149 Expired - Fee Related US6171549B1 (en) 1993-07-22 1995-12-15 Method for sterilizing products
US09/570,929 Expired - Fee Related US6346216B1 (en) 1993-07-22 2000-05-15 Method for sterilizing products
US09/985,606 Expired - Fee Related US6635222B2 (en) 1993-07-22 2001-11-05 Method of sterilizing products
US10/341,355 Abandoned US20030143107A1 (en) 1993-07-22 2003-01-14 Method for sterilizing products
US11/843,165 Abandoned US20080176306A1 (en) 1993-07-22 2007-08-22 Methods for Sterilizing Biological Materials

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US08/095,698 Expired - Lifetime US5362442A (en) 1993-07-22 1993-07-22 Method for sterilizing products with gamma radiation
US08/573,149 Expired - Fee Related US6171549B1 (en) 1993-07-22 1995-12-15 Method for sterilizing products
US09/570,929 Expired - Fee Related US6346216B1 (en) 1993-07-22 2000-05-15 Method for sterilizing products
US09/985,606 Expired - Fee Related US6635222B2 (en) 1993-07-22 2001-11-05 Method of sterilizing products
US10/341,355 Abandoned US20030143107A1 (en) 1993-07-22 2003-01-14 Method for sterilizing products

Country Status (15)

Country Link
US (6) US5362442A (en)
EP (1) EP0710124B1 (en)
JP (1) JPH09500553A (en)
KR (1) KR100389846B1 (en)
AT (1) AT235262T (en)
AU (1) AU687425B2 (en)
BR (1) BR9407138A (en)
CA (1) CA2167528C (en)
DE (2) DE69432351D1 (en)
DK (1) DK0710124T3 (en)
ES (1) ES2197907T3 (en)
FI (1) FI960281A (en)
NZ (1) NZ269786A (en)
PT (1) PT710124E (en)
WO (1) WO1995003071A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080220492A1 (en) * 2006-09-08 2008-09-11 Manders Ernest K Stabilization of biological materials through inactivation of metalloenzymes
US20100086576A1 (en) * 2008-10-06 2010-04-08 Myntti Matthew F Antimicrobial composition and methods of making and using same

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067157A1 (en) * 1993-07-22 2004-04-08 Clearant, Inc. Methods for sterilizing biological materials
US5362442A (en) 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US5548066A (en) * 1994-12-02 1996-08-20 Central Biomedia, Inc. Failure of passive transfer immune serum and method of making same
US6770278B1 (en) * 1994-12-02 2004-08-03 Central Biomedia, Inc. Methods of making and using immunoglobulin (Ig) compositions
DE19543503C2 (en) * 1995-11-22 2000-01-05 Nukem Gmbh Method and device for irradiating fluids with high-energy radiation, and use of the device
US6403124B1 (en) 1997-04-16 2002-06-11 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6482585B2 (en) * 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6637438B1 (en) 1997-04-21 2003-10-28 Kerry Scott Lane Method for assay and removal of harmful toxins during processing of tobacco products
US6058940A (en) * 1997-04-21 2000-05-09 Lane; Kerry Scott Method and system for assay and removal of harmful toxins during processing of tobacco products
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US6187000B1 (en) * 1998-08-20 2001-02-13 Endius Incorporated Cannula for receiving surgical instruments
AT411011T (en) * 1998-11-02 2008-10-15 Elan Pharma Int Ltd Multiparticulate composition of methylphenidate with modified release
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US6524528B1 (en) * 1999-03-02 2003-02-25 Suzanne C. Gottuso Method of sterilizing a tattooing solution through irradiation
US6713773B1 (en) 1999-10-07 2004-03-30 Mitec, Inc. Irradiation system and method
US6429608B1 (en) 2000-02-18 2002-08-06 Mitec Incorporated Direct injection accelerator method and system
AU4533801A (en) 2000-02-24 2001-09-03 Mitec Inc Bulk material irradiation system and method
US6707049B1 (en) 2000-03-21 2004-03-16 Mitec Incorporated Irradiation system with compact shield
US20030012687A1 (en) * 2000-03-23 2003-01-16 Macphee Martin J. Methods of sterilizing biological materials
AU5903101A (en) * 2000-03-23 2001-10-03 Clearant Inc Methods for sterilizing biological materials
US6682695B2 (en) * 2001-03-23 2004-01-27 Clearant, Inc. Methods for sterilizing biological materials by multiple rates
US20040086420A1 (en) * 2000-03-23 2004-05-06 Macphee Martin J. Methods for sterilizing serum or plasma
WO2001087357A2 (en) * 2000-05-17 2001-11-22 The American National Red Cross Gamma irradiation of protein-based pharmaceutical products
US20020098182A1 (en) * 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
US20070281037A9 (en) * 2000-09-28 2007-12-06 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
IL155097D0 (en) * 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US7632522B2 (en) 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US7381976B2 (en) 2001-03-13 2008-06-03 Triton Thalassic Technologies, Inc. Monochromatic fluid treatment systems
US8372016B2 (en) 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
CA2443150A1 (en) * 2001-04-02 2002-10-10 Mitec Incorporated Irradiation system and method
US7154103B2 (en) * 2001-04-02 2006-12-26 Mitec Incorporated Method of providing extended shelf life fresh meat products
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
WO2002100460A2 (en) 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Electric lancet actuator
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
EP1404233B1 (en) 2001-06-12 2009-12-02 Pelikan Technologies Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
WO2002100254A2 (en) 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US6696060B2 (en) * 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US6683319B1 (en) 2001-07-17 2004-01-27 Mitec Incorporated System and method for irradiation with improved dosage uniformity
WO2003011058A1 (en) * 2001-07-31 2003-02-13 Institut National De La Recherche Scientifique Formulations of compounds derived from natural sources and their use with irradiation for food preservation
US6946098B2 (en) 2001-08-10 2005-09-20 Clearant, Inc. Methods for sterilizing biological materials
US20030031584A1 (en) * 2001-08-10 2003-02-13 Wilson Burgess Methods for sterilizing biological materials using dipeptide stabilizers
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
US20110091353A1 (en) * 2001-09-24 2011-04-21 Wilson Burgess Methods for Sterilizing Tissue
US20030064000A1 (en) * 2001-09-24 2003-04-03 Wilson Burgess Methods of sterilizing biological mixtures using stabilizer mixtures
US20030095890A1 (en) * 2001-09-24 2003-05-22 Shirley Miekka Methods for sterilizing biological materials containing non-aqueous solvents
US20030059338A1 (en) * 2001-09-24 2003-03-27 Mann David M. Methods for sterilizing biological materials using flavonoid/flavonol stabilizers
US6783968B2 (en) 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
US20030124023A1 (en) * 2001-12-21 2003-07-03 Wilson Burgess Method of sterilizing heart valves
US20030185702A1 (en) * 2002-02-01 2003-10-02 Wilson Burgess Methods for sterilizing tissue
US20030180181A1 (en) * 2002-02-01 2003-09-25 Teri Greib Methods for sterilizing tissue
IL164191D0 (en) * 2002-03-26 2005-12-18 Nanocyte Inc Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosme tic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue nanocyte inc.
WO2003086480A1 (en) * 2002-04-10 2003-10-23 Clearant, Inc. Methods for sterilizing biological materials
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
WO2004043338A2 (en) * 2002-05-10 2004-05-27 The Ohio State University Flavin n-oxides: new anti-cancer agents and pathogen eradication agents
KR20070118200A (en) * 2002-06-07 2007-12-13 프로메테안 라이프사이언시즈, 인코포레이티드 Sterilization, stabilization and preservation of functional biologics
AU2007205748B2 (en) * 2002-06-07 2009-11-26 Promethean Lifesciences, Inc. Sterilization, stabilization and preservation of functional biologics
US20040013562A1 (en) * 2002-07-18 2004-01-22 Wilson Burgess Methods for sterilizing milk.
US20040013561A1 (en) * 2002-07-18 2004-01-22 David Mann Methods for sterilizing recombinant or transgenic material
US6908591B2 (en) * 2002-07-18 2005-06-21 Clearant, Inc. Methods for sterilizing biological materials by irradiation over a temperature gradient
JP2006501936A (en) * 2002-10-04 2006-01-19 エラン ファーマ インターナショナル,リミティド Gamma irradiation of solid nanoparticulate active agent
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
EP1569511A1 (en) * 2002-12-11 2005-09-07 CryoLife, Inc. Radical retardant cryopreservation solutions
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US8828226B2 (en) 2003-03-01 2014-09-09 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
JP2007501683A (en) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド Sterilization of nanoparticulate active agent dispersions according to γ-irradiation
AT476137T (en) 2003-05-30 2010-08-15 Pelikan Technologies Inc Method and device for injecting liquid
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
WO2005030137A2 (en) * 2003-09-24 2005-04-07 The University Of Toledo, A University Instrumentality Of The State Of Ohio Improving biomechanical performance of irradiated biological material
WO2005033659A2 (en) 2003-09-29 2005-04-14 Pelikan Technologies, Inc. Method and apparatus for an improved sample capture device
WO2005037095A1 (en) 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
US20050129569A1 (en) * 2003-12-15 2005-06-16 Becton, Dickinson And Company Terminal sterilization of prefilled containers
WO2005065414A2 (en) 2003-12-31 2005-07-21 Pelikan Technologies, Inc. Method and apparatus for improving fluidic flow and sample capture
EP1711053A2 (en) * 2004-02-02 2006-10-18 I.M.T. Interface Multigrad Technology Ltd. Biological material and methods and solutions for preservation thereof
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
ES2526092T3 (en) * 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Injectable formulations of olanzapine nanoparticles
CN1298227C (en) * 2004-12-30 2007-02-07 上海三生生物技术有限公司 Effective sterilizing method capable of keeping colostrum immune globulin activity
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
JP2006289071A (en) * 2005-03-18 2006-10-26 Toray Ind Inc Sterilization method for compound
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
WO2006130869A1 (en) * 2005-06-02 2006-12-07 Alza Corporation Method for terminal sterilization of transdermal delivery devices
US20060280644A1 (en) * 2005-06-02 2006-12-14 Scott Sellers Method for terminal sterilization of transdermal delivery devices
US20070237866A1 (en) * 2006-03-10 2007-10-11 Mitec Incorporated Process for the extension of microbial life and color life of fresh meat products
US20080317843A1 (en) * 2006-07-12 2008-12-25 Elan Corporation Plc Nanoparticulate formulations of modafinil
US8580192B2 (en) * 2006-10-31 2013-11-12 Ethicon, Inc. Sterilization of polymeric materials
US7776260B2 (en) * 2006-12-11 2010-08-17 Ethicon, Inc. Apparatus and method for the irradiation of radiation sensitive materials
US7704453B2 (en) * 2007-06-07 2010-04-27 Ethicon, Inc. Method for establishing a sterilizing dose for radiation sensitive products
US8409499B2 (en) * 2007-06-07 2013-04-02 Ethicon, Inc. Method for establishing a sterilizing dose for radiation sensitive products
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
CA2781874A1 (en) 2009-10-12 2011-04-21 New Health Sciences, Inc. Oxygen depletion devices and methods for removing oxygen from red blood cells
CN102711865B (en) 2009-10-12 2015-08-19 新健康科学股份有限公司 Blood storage bag system and the consuming device having an oxygen and carbon dioxide consumption capacity
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
EP2539435A2 (en) * 2010-02-23 2013-01-02 Corning Incorporated Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
CN101862452B (en) * 2010-07-22 2012-06-20 山西芮城亚宝兽药有限公司 Method for preparing swine multi-valent antiserum compound preparation
US9339025B2 (en) 2010-08-25 2016-05-17 New Health Sciences, Inc. Method for enhancing red blood cell quality and survival during storage
JP5859558B2 (en) 2010-11-05 2016-02-10 ニュー・ヘルス・サイエンシーズ・インコーポレイテッドNew Health Sciences, Inc. Save irradiation and anaerobic erythrocytes
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
CA2844449A1 (en) 2011-08-10 2013-02-14 New Health Sciences, Inc. Integrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device
BR112014019927A8 (en) 2012-02-17 2018-01-16 Alcresta Inc nutritional formula, said formula the method of preparation before ingestion by an individual using said formula, device and prepare it to the container
EP2961269A1 (en) 2013-02-28 2016-01-06 New Health Sciences, Inc. Gas depletion and gas addition devices for blood treatment
JPWO2016051962A1 (en) * 2014-10-02 2017-07-20 テルモ株式会社 Medical container for containing a protein solution formulation
CA2978940A1 (en) 2015-03-10 2016-09-15 New Health Sciences, Inc. Oxygen reduction disposable kits, devices and methods of use thereof
EP3285711A4 (en) 2015-04-23 2018-11-07 New Health Sciences, Inc. Anaerobic blood storage containers
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use

Citations (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE23195E (en) * 1950-02-07 Preserving
US2832689A (en) * 1952-01-24 1958-04-29 Research Corp Preservation of organic materials by irradiation
US2920969A (en) * 1954-08-25 1960-01-12 Gen Electric Method and means for irradiating foods
US2962380A (en) * 1956-10-08 1960-11-29 Research Corp Radiation sterilization of fluid food products
US3620944A (en) * 1967-09-09 1971-11-16 Osaka Prefecture Process of purifying water by irradiating it
US3743480A (en) * 1971-04-09 1973-07-03 Allied Chem Sterilization of biological fluids
US3779706A (en) * 1971-10-04 1973-12-18 Energy Sciences Inc Process for bulk sterilization, minimizing chemical and physical damage
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4251437A (en) * 1978-11-01 1981-02-17 Nordisk Insulinlaboratorium Process for producing an antihemophilic factor preparation from human blood plasma by irradiating with electromagnetic waves
US4282863A (en) * 1978-07-20 1981-08-11 Beigler Myron A Methods of preparing and using intravenous nutrient compositions
US4330626A (en) * 1980-03-19 1982-05-18 The Enzyme Center, Inc. Method of preparing high-activity, low-bacteria, urease enzyme
US4336247A (en) * 1978-09-05 1982-06-22 Eriksen Arthur E Body system nutrient material
US4370264A (en) * 1980-09-10 1983-01-25 Biotest-Serum-Institut Gmbh Method for the cold sterilization of preparations containing blood coagulation factor VIII
US4409105A (en) * 1980-12-18 1983-10-11 Asahi Kasei Kogyo Kabushiki Kaisha Dried, sterilized, gamma-globulin-fixed column and a process for preparing the same
US4472840A (en) * 1981-09-21 1984-09-25 Jefferies Steven R Method of inducing osseous formation by implanting bone graft material
US4620908A (en) * 1983-10-03 1986-11-04 Biocell Laboratories, Inc. Method for destroying microbial contamination in protein materials
US4784850A (en) * 1985-09-04 1988-11-15 Mutzarei Maabarot Process for preparing antibodies against E. Coli K-99 antigen from bovine milk
US4798611A (en) * 1986-10-14 1989-01-17 Hancock Jaffe Laboratories Enhancement of xenogeneic tissue
US4865602A (en) * 1986-11-06 1989-09-12 Collagen Corporation Gamma irradiation of collagen/mineral mixtures
US4931361A (en) * 1988-11-18 1990-06-05 California Institute Of Technology Cryoprotective reagents in freeze-drying membranes
US4933145A (en) * 1985-05-10 1990-06-12 Terumo Kabushiki Kaisha Apparatus for inhibiting glycolysis in blood samples
US4946648A (en) * 1987-09-11 1990-08-07 Biotest Pharma Gmbh Method of sterilizing plasma or plasma fractions
US4963356A (en) * 1982-10-13 1990-10-16 Minnesota Mining And Manufacturing Company Stable antigenic extracts methods
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
US5012503A (en) * 1986-11-05 1991-04-30 Sumitomo Bakelite Company, Ltd. Method for sterilization of polyvinyl alcohol gel by γ-ray
US5044091A (en) * 1989-04-18 1991-09-03 Sankyo Company, Limited Method of preparing a freeze-dried formulation containing a drug
US5106619A (en) * 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US5134295A (en) * 1990-04-19 1992-07-28 Waelischmiller Hans Irradiation apparatus
US5185371A (en) * 1986-03-10 1993-02-09 University Of Southern California Method for disinfecting red blood cells
US5226065A (en) * 1989-10-13 1993-07-06 Stericycle, Inc. Device for disinfecting medical materials
US5283034A (en) * 1989-06-29 1994-02-01 Applied Immune Sciences, Inc. Stabilization of sterilized surfaces for research and medical use
US5336616A (en) * 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US5362442A (en) * 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5460962A (en) * 1994-01-04 1995-10-24 Organogenesis Inc. Peracetic acid sterilization of collagen or collagenous tissue
US5510122A (en) * 1994-09-28 1996-04-23 The Research Foundation Of State University Of New York Preparation and use of whole saliva
US5548066A (en) * 1994-12-02 1996-08-20 Central Biomedia, Inc. Failure of passive transfer immune serum and method of making same
US5603894A (en) * 1994-10-31 1997-02-18 Abbott Laboratories Method of sterilizing a pharmaceutical composition
US5609864A (en) * 1990-09-04 1997-03-11 Shanbrom; Edward Preservation of blood, tissues and biological fluids
US5637451A (en) * 1995-03-29 1997-06-10 New York Blood Center, Inc. Photodynamic treatment of red blood cells with phthalocyanines and red light at higher light fluence rates is protective of red blood cells
US5643464A (en) * 1988-11-21 1997-07-01 Collagen Corporation Process for preparing a sterile, dry crosslinking agent
US5712086A (en) * 1990-05-15 1998-01-27 New York Blood Center, Inc. Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions
US5730933A (en) * 1996-04-16 1998-03-24 Depuy Orthopaedics, Inc. Radiation sterilization of biologically active compounds
US5817528A (en) * 1994-05-13 1998-10-06 Therasorb Medizinische Systeme Gmbh Sterile and pyrogen-free columns containing coupled protein for binding and removal of substances from blood
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5856172A (en) * 1997-01-03 1999-01-05 Quality Technologies, Llc Preservation of microorganisms in a vial with a cap comprising an immobilized desiccant
US5881534A (en) * 1994-06-08 1999-03-16 Pharmacia & Upjohn Ab Process for sterilization by radiation and by the use of an oxygen absorber, a container and a medical article sterilized by the process
US5981163A (en) * 1990-05-15 1999-11-09 New York Blood Center, Inc. Process for the sterilization of biological compositions using irradiation and quenchers of type I and type II photodynamic reactions
US5986168A (en) * 1995-04-25 1999-11-16 Nicem, Ltd. Prosthesis containing bioabsorbable materials insolubilized without chemical reagents and method of making the same
US5989498A (en) * 1994-03-04 1999-11-23 St. Jude Medical, Inc. Electron-beam sterilization of biological materials
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
US6046024A (en) * 1995-11-09 2000-04-04 E. R. Squibb & Sons, Inc. Method of producing a fibrin monomer using a biotinylated enzyme and immobilized avidin
US6049025A (en) * 1995-09-15 2000-04-11 Stone; Kevin R. Articular cartilage xenografts
US6060233A (en) * 1996-06-14 2000-05-09 Biostore New Zealand, Ltd Methods for the lyophilization of platelets, platelet membranes or erythrocytes
US6066626A (en) * 1997-10-29 2000-05-23 Genzyme Corporation Compositions and method for treating lysosomal storage disease
US6087141A (en) * 1990-05-15 2000-07-11 New York Blood Center, Inc. Process for the sterilization of biological compositions and the product produced thereby
US6120592A (en) * 1997-04-25 2000-09-19 Brault; Denis Biodegradable films containing caseinate and their method of manufacture by irradiation
US6159490A (en) * 1996-09-04 2000-12-12 Deghenghi; Romano Implants containing bioactive peptides
US6187572B1 (en) * 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US6190855B1 (en) * 1996-10-28 2001-02-20 Baxter International Inc. Systems and methods for removing viral agents from blood
US6197207B1 (en) * 1997-05-21 2001-03-06 Baxter International Inc. Method of reducing the possibility of transmission of spongiform encephalopathy diseases by blood products
US6203544B1 (en) * 1997-11-19 2001-03-20 Tutogen Medical, Inc. Fixation element
US6235508B1 (en) * 1995-06-07 2001-05-22 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US6258821B1 (en) * 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
US20010049141A1 (en) * 1997-02-14 2001-12-06 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US20020064807A1 (en) * 1996-12-10 2002-05-30 Badylak Stephen F. Gastric submucosal tissue as a novel diagnostic tool
US20020106394A1 (en) * 1995-06-07 2002-08-08 Tucker Marjorie M. Terminally sterilized osteogenic devices and preparation thereof
US20020188319A1 (en) * 2001-06-08 2002-12-12 Morris Edward J. Method and apparatus for sealing access
US20030068815A1 (en) * 1999-02-11 2003-04-10 Stone Kevin R. Sterilized xenograft tissue

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1321420A1 (en) * 1985-06-19 1987-07-07 Московский научно-исследовательский институт микрохирургии глаза Method of collagen coating for ophthalmological use
CA1331562C (en) 1987-09-28 1994-08-23 Hans Draayer Vaccine
GB8807187D0 (en) * 1988-03-25 1988-04-27 Harrison J F Improvements in/relating to inactivation of infectious agents
GB8817240D0 (en) * 1988-07-20 1988-08-24 Univ Salford Business Services Sterilising methods
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
IL97856D0 (en) * 1990-04-16 1992-06-21 Cryopharm Corp Compositions containing cellular blood matter and method and processes for the inactivation of viral and bacterial blood components
CA2056619C (en) 1990-04-16 2002-07-30 Roger W. Hackett Method of inactivation of viral and bacterial blood contaminants
US6000044A (en) 1997-11-26 1999-12-07 Digital Equipment Corporation Apparatus for randomly sampling instructions in a processor pipeline
DE19849984A1 (en) 1998-10-29 2000-05-04 Tutogen Medical Inc A process for the preparation of bone material
DE29913200U1 (en) 1999-07-28 1999-09-23 Tutogen Medical Gmbh Implant made of bone material
MXPA02001652A (en) 1999-08-17 2002-08-06 Mobile Process Technology Co Recovery process for oxidation catalyst in the manufacture of aromatic carboxylic acids.
DE19952550A1 (en) 1999-11-02 2001-05-03 Tutogen Medical Gmbh bone implant
DE19952939A1 (en) 1999-11-03 2001-05-10 Tutogen Medical Gmbh Implant made of bone material
DE19962248A1 (en) 1999-12-22 2001-06-28 Tutogen Medical Gmbh Producing bone material containing bone morphogenic protein, useful as transplant for accelerating bone growth, includes resorbable material for sustained release of protein
US6379385B1 (en) 2000-01-06 2002-04-30 Tutogen Medical Gmbh Implant of bone matter
DE10014616A1 (en) 2000-03-24 2001-09-27 Tutogen Medical Gmbh Cranium implant for use in brain surgery consists of a plate of spongy, cortical or compact bone material of human or animal origin preferably obtained by dehydration
DE10014617A1 (en) 2000-03-24 2001-09-27 Tutogen Medical Gmbh Orthopedic interference screw especially useful in crucial ligament repair has both the screw body and head made from human or animal bone preferably obtained by dehydration
DE10026306A1 (en) 2000-05-26 2001-11-29 Tutogen Medical Gmbh Jawbone transplant is domed and can be bent to U-shapes and is made of spongiose, cortical or compact bone material of human or animal origin

Patent Citations (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE23195E (en) * 1950-02-07 Preserving
US2832689A (en) * 1952-01-24 1958-04-29 Research Corp Preservation of organic materials by irradiation
US2920969A (en) * 1954-08-25 1960-01-12 Gen Electric Method and means for irradiating foods
US2962380A (en) * 1956-10-08 1960-11-29 Research Corp Radiation sterilization of fluid food products
US3620944A (en) * 1967-09-09 1971-11-16 Osaka Prefecture Process of purifying water by irradiating it
US3743480A (en) * 1971-04-09 1973-07-03 Allied Chem Sterilization of biological fluids
US3779706A (en) * 1971-10-04 1973-12-18 Energy Sciences Inc Process for bulk sterilization, minimizing chemical and physical damage
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4282863A (en) * 1978-07-20 1981-08-11 Beigler Myron A Methods of preparing and using intravenous nutrient compositions
US4336247A (en) * 1978-09-05 1982-06-22 Eriksen Arthur E Body system nutrient material
US4251437A (en) * 1978-11-01 1981-02-17 Nordisk Insulinlaboratorium Process for producing an antihemophilic factor preparation from human blood plasma by irradiating with electromagnetic waves
US4330626A (en) * 1980-03-19 1982-05-18 The Enzyme Center, Inc. Method of preparing high-activity, low-bacteria, urease enzyme
US4370264A (en) * 1980-09-10 1983-01-25 Biotest-Serum-Institut Gmbh Method for the cold sterilization of preparations containing blood coagulation factor VIII
US4409105A (en) * 1980-12-18 1983-10-11 Asahi Kasei Kogyo Kabushiki Kaisha Dried, sterilized, gamma-globulin-fixed column and a process for preparing the same
US4472840A (en) * 1981-09-21 1984-09-25 Jefferies Steven R Method of inducing osseous formation by implanting bone graft material
US4963356A (en) * 1982-10-13 1990-10-16 Minnesota Mining And Manufacturing Company Stable antigenic extracts methods
US4620908A (en) * 1983-10-03 1986-11-04 Biocell Laboratories, Inc. Method for destroying microbial contamination in protein materials
US5106619A (en) * 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US4933145A (en) * 1985-05-10 1990-06-12 Terumo Kabushiki Kaisha Apparatus for inhibiting glycolysis in blood samples
US4784850A (en) * 1985-09-04 1988-11-15 Mutzarei Maabarot Process for preparing antibodies against E. Coli K-99 antigen from bovine milk
US5185371A (en) * 1986-03-10 1993-02-09 University Of Southern California Method for disinfecting red blood cells
US4798611A (en) * 1986-10-14 1989-01-17 Hancock Jaffe Laboratories Enhancement of xenogeneic tissue
US5012503A (en) * 1986-11-05 1991-04-30 Sumitomo Bakelite Company, Ltd. Method for sterilization of polyvinyl alcohol gel by γ-ray
US4865602A (en) * 1986-11-06 1989-09-12 Collagen Corporation Gamma irradiation of collagen/mineral mixtures
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
US4946648A (en) * 1987-09-11 1990-08-07 Biotest Pharma Gmbh Method of sterilizing plasma or plasma fractions
US4931361A (en) * 1988-11-18 1990-06-05 California Institute Of Technology Cryoprotective reagents in freeze-drying membranes
US5643464A (en) * 1988-11-21 1997-07-01 Collagen Corporation Process for preparing a sterile, dry crosslinking agent
US5044091A (en) * 1989-04-18 1991-09-03 Sankyo Company, Limited Method of preparing a freeze-dried formulation containing a drug
US5044091B1 (en) * 1989-04-18 1997-12-30 Sankyo Co Method of preparing a freeze-dried formulation of a drug
US5283034A (en) * 1989-06-29 1994-02-01 Applied Immune Sciences, Inc. Stabilization of sterilized surfaces for research and medical use
US5226065A (en) * 1989-10-13 1993-07-06 Stericycle, Inc. Device for disinfecting medical materials
US6187572B1 (en) * 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5134295A (en) * 1990-04-19 1992-07-28 Waelischmiller Hans Irradiation apparatus
US6087141A (en) * 1990-05-15 2000-07-11 New York Blood Center, Inc. Process for the sterilization of biological compositions and the product produced thereby
US6214534B1 (en) * 1990-05-15 2001-04-10 New York Blood Center, Inc. Biological compositions containing quenchers of type I and type II photodynamic reactions
US5981163A (en) * 1990-05-15 1999-11-09 New York Blood Center, Inc. Process for the sterilization of biological compositions using irradiation and quenchers of type I and type II photodynamic reactions
US5712086A (en) * 1990-05-15 1998-01-27 New York Blood Center, Inc. Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions
US5609864A (en) * 1990-09-04 1997-03-11 Shanbrom; Edward Preservation of blood, tissues and biological fluids
US5336616A (en) * 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US6171549B1 (en) * 1993-07-22 2001-01-09 Sterisure, Inc. Method for sterilizing products
US5362442A (en) * 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
US5460962A (en) * 1994-01-04 1995-10-24 Organogenesis Inc. Peracetic acid sterilization of collagen or collagenous tissue
US5989498A (en) * 1994-03-04 1999-11-23 St. Jude Medical, Inc. Electron-beam sterilization of biological materials
US5817528A (en) * 1994-05-13 1998-10-06 Therasorb Medizinische Systeme Gmbh Sterile and pyrogen-free columns containing coupled protein for binding and removal of substances from blood
US5881534A (en) * 1994-06-08 1999-03-16 Pharmacia & Upjohn Ab Process for sterilization by radiation and by the use of an oxygen absorber, a container and a medical article sterilized by the process
US5510122A (en) * 1994-09-28 1996-04-23 The Research Foundation Of State University Of New York Preparation and use of whole saliva
US5603894A (en) * 1994-10-31 1997-02-18 Abbott Laboratories Method of sterilizing a pharmaceutical composition
US5548066A (en) * 1994-12-02 1996-08-20 Central Biomedia, Inc. Failure of passive transfer immune serum and method of making same
US5637451A (en) * 1995-03-29 1997-06-10 New York Blood Center, Inc. Photodynamic treatment of red blood cells with phthalocyanines and red light at higher light fluence rates is protective of red blood cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5986168A (en) * 1995-04-25 1999-11-16 Nicem, Ltd. Prosthesis containing bioabsorbable materials insolubilized without chemical reagents and method of making the same
US20020106394A1 (en) * 1995-06-07 2002-08-08 Tucker Marjorie M. Terminally sterilized osteogenic devices and preparation thereof
US6235508B1 (en) * 1995-06-07 2001-05-22 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US6049025A (en) * 1995-09-15 2000-04-11 Stone; Kevin R. Articular cartilage xenografts
US6046024A (en) * 1995-11-09 2000-04-04 E. R. Squibb & Sons, Inc. Method of producing a fibrin monomer using a biotinylated enzyme and immobilized avidin
US5730933A (en) * 1996-04-16 1998-03-24 Depuy Orthopaedics, Inc. Radiation sterilization of biologically active compounds
US6060233A (en) * 1996-06-14 2000-05-09 Biostore New Zealand, Ltd Methods for the lyophilization of platelets, platelet membranes or erythrocytes
US6159490A (en) * 1996-09-04 2000-12-12 Deghenghi; Romano Implants containing bioactive peptides
US6190855B1 (en) * 1996-10-28 2001-02-20 Baxter International Inc. Systems and methods for removing viral agents from blood
US20020064807A1 (en) * 1996-12-10 2002-05-30 Badylak Stephen F. Gastric submucosal tissue as a novel diagnostic tool
US5856172A (en) * 1997-01-03 1999-01-05 Quality Technologies, Llc Preservation of microorganisms in a vial with a cap comprising an immobilized desiccant
US20010049141A1 (en) * 1997-02-14 2001-12-06 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US6120592A (en) * 1997-04-25 2000-09-19 Brault; Denis Biodegradable films containing caseinate and their method of manufacture by irradiation
US6197207B1 (en) * 1997-05-21 2001-03-06 Baxter International Inc. Method of reducing the possibility of transmission of spongiform encephalopathy diseases by blood products
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
US6066626A (en) * 1997-10-29 2000-05-23 Genzyme Corporation Compositions and method for treating lysosomal storage disease
US6203544B1 (en) * 1997-11-19 2001-03-20 Tutogen Medical, Inc. Fixation element
US20030068815A1 (en) * 1999-02-11 2003-04-10 Stone Kevin R. Sterilized xenograft tissue
US6258821B1 (en) * 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
US20020188319A1 (en) * 2001-06-08 2002-12-12 Morris Edward J. Method and apparatus for sealing access

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080220492A1 (en) * 2006-09-08 2008-09-11 Manders Ernest K Stabilization of biological materials through inactivation of metalloenzymes
US20100086576A1 (en) * 2008-10-06 2010-04-08 Myntti Matthew F Antimicrobial composition and methods of making and using same
US8940792B2 (en) 2008-10-06 2015-01-27 Next Science, Llc Antimicrobial composition and methods for using same

Also Published As

Publication number Publication date
US6635222B2 (en) 2003-10-21
PT710124E (en) 2003-08-29
AU687425B2 (en) 1998-02-26
FI960281A (en) 1996-03-18
DE69432351T2 (en) 2004-02-19
US6346216B1 (en) 2002-02-12
CA2167528C (en) 2005-02-01
JPH09500553A (en) 1997-01-21
US20030059339A1 (en) 2003-03-27
ES2197907T3 (en) 2004-01-16
KR100389846B1 (en) 2003-10-30
DE69432351D1 (en) 2003-04-30
FI960281D0 (en)
NZ269786A (en) 1998-03-25
US6171549B1 (en) 2001-01-09
AT235262T (en) 2003-04-15
US20030143107A1 (en) 2003-07-31
WO1995003071A1 (en) 1995-02-02
US5362442A (en) 1994-11-08
CA2167528A1 (en) 1995-02-02
EP0710124A1 (en) 1996-05-08
BR9407138A (en) 1996-09-17
AU7343494A (en) 1995-02-20
DK710124T3 (en)
FI960281A0 (en) 1996-01-19
DK0710124T3 (en) 2003-07-21
EP0710124B1 (en) 2003-03-26

Similar Documents

Publication Publication Date Title
LoGrippo Investigations of the use of beta‐propiolactone in virus inactivation
CA2301067C (en) Rapid cryobaric sterilization and vaccine preparation
JP2831155B2 (en) Photodynamic inactivation of viruses in cell-containing composition
US5360734A (en) Method for inactivating pathogens in erythrocytes using photoactive compounds and plasma protein reduction
ES2224415T3 (en) Methods to inhibit pathogens in biological materials deactivators.
JP4464939B2 (en) Method and apparatus for inactivating biological contaminants using photosensitizer
Pelletier et al. Pathogen inactivation techniques
JP3502095B2 (en) Decontamination of blood components by 8-methoxy-flop psoralen
US7118852B2 (en) Methods and apparatus for decontaminating fluids
Corbin Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer
US5658722A (en) Process for the sterilization of biological compositions using UVA1 irradiation
AU2001236787B2 (en) Protecting molecules in biologically derived compositions while treating with broad-spectrum pulsed light
US6187572B1 (en) Method of inactivation of viral and bacterial blood contaminants
Ruane et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light
US5618662A (en) Intravenous administration of psoralen
Cardo et al. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light
ES2212288T3 (en) Improved storage and maintenance of blood products.
US5232844A (en) Photodynamic inactivation of viruses in cell-containing compositions
US5709991A (en) Proralen inactivation of microorganisms and psoralen removal
Goodrich et al. The Mirasol™ PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends
WO1995002324A1 (en) Method of inactivation of viral and bacterial blood contaminants
ES2290957T3 (en) Installation deactivation of viral contaminants in blood products.
JP4307255B2 (en) How to sterilize the digestive enzyme preparation
US5281392A (en) Method for disinfecting red blood cells, blood products, and corneas
HU211545A9 (en) A blood product, a method of producing the same, and a method of determining the virus inactivation capacity of an inactivation treatment